NCLAT: Can’t Dismiss Restoration App. if Filed in 30 Days from Date of Dismissal of Original App.  ||  Delhi HC: Communication between Parties through Whatsapp Constitute Valid Agreement  ||  Delhi HC Seeks Response from Govt. Over Penalties on Petrol Pumps Supplying Fuel to Old Vehicles  ||  Centre Notifies "Unified Waqf Management, Empowerment, Efficiency and Development Rules, 2025"  ||  Del. HC: Can’t Reject TM Owner’s Claim Merely because Defendant Could have Sought Removal of Mark  ||  Bombay HC: Cannot Treat Sole Director of OPC, Parallelly with Separate Legal Entity  ||  Delhi HC: Can Apply 'Family of Marks' Concept to Injunct Specific Marks  ||  HP HC: Can’t Set Aside Ex-Parte Decree for Mere Irregularity  ||  Cal. HC: Order by HC Bench Not Conferred With Determination by Roster is Void  ||  Calcutta HC: Purchase Order Including Arbitration Agreement to Prevail Over Tax Invoice Lacking it    

Delhi HC Restrains Glenmark Pharmaceuticals from Manufacturing, Selling Zita and Zita-Met - (07 Oct 2015)

Delhi High Court has restrained Glenmark Pharmaceuticals, an Indian firm, from manufacturing and selling its anti-diabetes drugs Zita and Zita-Met, saying it has infringed patent of the American company Merck Sharp and Dohme.

Tags : DELHI HIGH COURT  GLENMARK PHARMACEUTICALS   MERCK SHARP AND DOHME   PATENT  

Share :        

Disclaimer | Copyright 2025 - All Rights Reserved